RxDoctor Payments Data

Wesley Williams, MD

Family Medicine · Midwest City, OKNPI 1205802105

Payments from drug & device makers

$373in general payments, 2019–2025

Across 23 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$184
  • Pfizer$55
  • Novo Nordisk$52
  • Boston Scientific$32
  • Abbott$21
  • GSK$17
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$373100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)12$184
Pfizer3$55
Novo Nordisk4$52
Boston Scientific1$32
Abbott1$21
GSK1$17
Amgen1$12

How this compares

$373 in reported general payments places this provider in the 50th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$42,422
Medicare patients
93
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$131,583
EliquisApixaban120$97,063
Humira PenAdalimumab13$86,932
FarxigaDapagliflozin Propanediol30$27,225
JardianceEmpagliflozin16$27,204
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,459
XareltoRivaroxaban18$25,040
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$20,965
MounjaroTirzepatide13$15,202
Tresiba Flextouch U-100Insulin Degludec19$14,013
JanuviaSitagliptin Phosphate17$13,630
Atrovent HfaIpratropium Bromide13$13,180
TrulicityDulaglutide11$12,160
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$11,673
Atorvastatin Calcium425$10,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$131,583110 claims
PfizerEliquis$55$97,063120 claims
GSKTrelegy Ellipta$17$26,45929 claims
AbbVieLinzess$184$8,08615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →